A Phase 3 interventional study of Valbenazine and Placebo in Chorea, Huntington, sponsored by Neurocrine Biosciences. Completed at 46 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-11.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 24th largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2019, is one of 14 in phase 3, and was the 90th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
Neurocrine Biosciences has 3 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule, administered orally once daily for 12 weeks.
Drug: Valbenazine
Capsule, administered orally once daily for 12 weeks.
Drug: Placebo
vesicular monoamine transporter 2 (VMAT2) inhibitor
Also known as: NBI-98854
non-active dosage form
Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score.
The TMC is part of the motor assessment of the UHDRS and measures chorea in 7 different body parts including the face, oral-buccal-lingual region, trunk and each limb independently. The TMC score is the sum of the individual scores and ranges from 0 to 28. A decrease in TMC scores indicates improvement in chorea symptoms.
Time frame: Baseline (average of screening and Day -1), maintenance (average of Weeks 10 and 12)
Percent of Clinical Global Impression of Change (CGI-C) Responders at Week 12
The CGI-C is a 7-point scale that rates the overall global change in chorea symptoms since the initiation of study drug dosing, ranging from 1 (very much improved) to 7 (very much worse), as assessed by the investigator or qualified clinician designee. Participants whose CGI-C score was either a 1 (very much improved) or a 2 (much improved) were classified as responders.
Time frame: Week 12
Percent of Patient Global Impression of Change (PGI-C) Responders at Week 12
The PGI-C is a 7-point scale that rates the overall global change in chorea symptoms since the initiation of study drug dosing, ranging from 1 (very much improved) to 7 (very much worse), as assessed by the participant. Participants whose PGI-C score was either a 1 (very much improved) or a 2 (much improved) were classified as responders.
Time frame: Week 12
Change From Baseline to Week 12 in the Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function T-Score
The Neuro-QoL Upper Extremity Function Short Form consists of 8 questions about physical abilities, rated from 1 (unable to do) to 5 (without any difficulty). The Neuro-QoL scores were standardized as T-scores with a mean of 50 and standard deviation of 10. Scores below 50 indicated below average upper extremity function. The change from baseline to Week 12 in the Neuro-QoL Upper Extremity Function T-score are presented here. An increase in score indicates increased function.
Time frame: Baseline, Week 12
Change From Baseline to Week 12 in the Neuro-QoL Lower Extremity Function T-Score
The Neuro-QoL Lower Extremity Function Short Form consists of 8 questions about physical abilities, rated from 1 (unable to do) to 5 (without any difficulty). The Neuro-QoL scores were standardized as T-scores with a mean of 50 and standard deviation of 10. Scores below 50 indicated below average upper extremity function. The change from baseline to Week 12 in the Neuro-QoL Upper Extremity Function T-score are presented here. An increase in score indicates better function.
Time frame: Baseline, Week 12
| Milestone | Valbenazine | Placebo |
|---|---|---|
| Started | 64 | 64 |
| Received at least 1 dose of study drug | 64 | 63 |
| Completed | 57 | 54 |
| Not completed | 7 | 10 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Discontinued due to covid-19-related study pause | 3 | 4 |
| Withdrew: Other than specified | 1 | 0 |
| Withdrew: Not dosed with study drug | 0 | 1 |
The TMC is part of the motor assessment of the UHDRS and measures chorea in 7 different body parts including the face, oral-buccal-lingual region, trunk and each limb independently. The TMC score is the sum of the individual scores and ranges from 0 to 28. A decrease in TMC scores indicates improvement in chorea symptoms.
| units on a scale | Valbenazine | Placebo |
|---|---|---|
| Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. | -4.60 ± 0.43 | -1.44 ± 0.44 |
The CGI-C is a 7-point scale that rates the overall global change in chorea symptoms since the initiation of study drug dosing, ranging from 1 (very much improved) to 7 (very much worse), as assessed by the investigator or qualified clinician designee. Participants whose CGI-C score was either a 1 (very much improved) or a 2 (much improved) were classified as responders.
| percentage of responders | Valbenazine | Placebo |
|---|---|---|
| Percent of Clinical Global Impression of Change (CGI-C) Responders at Week 12 | 42.9 | 13.2 |
The PGI-C is a 7-point scale that rates the overall global change in chorea symptoms since the initiation of study drug dosing, ranging from 1 (very much improved) to 7 (very much worse), as assessed by the participant. Participants whose PGI-C score was either a 1 (very much improved) or a 2 (much improved) were classified as responders.
| percentage of responders | Valbenazine | Placebo |
|---|---|---|
| Percent of Patient Global Impression of Change (PGI-C) Responders at Week 12 | 52.7 | 26.4 |
The Neuro-QoL Upper Extremity Function Short Form consists of 8 questions about physical abilities, rated from 1 (unable to do) to 5 (without any difficulty). The Neuro-QoL scores were standardized as T-scores with a mean of 50 and standard deviation of 10. Scores below 50 indicated below average upper extremity function. The change from baseline to Week 12 in the Neuro-QoL Upper Extremity Function T-score are presented here. An increase in score indicates increased function.
| units on a scale | Valbenazine | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function T-Score | -1.58 ± 1.01 | -3.00 ± 1.04 |
The Neuro-QoL Lower Extremity Function Short Form consists of 8 questions about physical abilities, rated from 1 (unable to do) to 5 (without any difficulty). The Neuro-QoL scores were standardized as T-scores with a mean of 50 and standard deviation of 10. Scores below 50 indicated below average upper extremity function. The change from baseline to Week 12 in the Neuro-QoL Upper Extremity Function T-score are presented here. An increase in score indicates better function.
| units on a scale | Valbenazine | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Neuro-QoL Lower Extremity Function T-Score | -0.27 ± 0.82 | 0.61 ± 0.84 |
Collected over Day 1 (after dosing) through Week 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valbenazine | 0/64 (0%) | 1/64 (1.6%) | 35/64 (54.7%) |
| Placebo | 1/63 (1.6%) | 2/63 (3.2%) | 17/63 (27%) |
| Event | Valbenazine | Placebo |
|---|---|---|
| Psychotic disorderPsychiatric disorders | 0/64 | 1/63 |
| Colon cancerCardiac disorders | 0/64 | 1/63 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/64 | 0/63 |
| Event | Valbenazine | Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 10/64 | 2/63 |
| FatigueGeneral disorders | 9/64 | 6/63 |
| FallInjury, poisoning and procedural complications | 8/64 | 8/63 |
| RashSkin and subcutaneous tissue disorders | 5/64 | 0/63 |
| UrticariaSkin and subcutaneous tissue disorders | 5/64 | 0/63 |
| AkathisiaNervous system disorders | 4/64 | 3/63 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Valbenazine | Placebo | Total |
|---|---|---|---|
| Mean | 54.1 ± 10.1 | 53.6 ± 11.6 | 53.8 ± 10.8 |
| Sex: Female, Male(Participants) | Valbenazine | Placebo | Total |
|---|---|---|---|
| Female | 33 | 36 | 69 |
| Male | 31 | 27 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Valbenazine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 59 | 60 | 119 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Valbenazine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 60 | 62 | 122 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Valbenazine | Placebo | Total |
|---|---|---|---|
| Canada | 2 | 7 | 9 |
| United States | 62 | 56 | 118 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2019 to primary completion in Oct 2021, 23 months.
Results were first posted in Oct 2023, 1 year 11 months after primary completion. A results delay was requested in Sep 2022.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine